Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of cutting the price of some drugs on the US market next year.
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
